UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-29621

NovAccess Global Inc.

(Exact name of registrant as specified in its charter)

Colorado	84-1384159
(State or other jurisdiction of incorporation or organization)	(I.R.S. employer Identification no.)

Address of principal executive offices, including zip code: 8584 E. Washington Street #127, Chagrin Falls, Ohio 44023

Registrant’s telephone number, including area code: (213) 642-9268

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☐ Smaller Reporting Company ☒ Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. There were 44,602,725 shares of common stock outstanding on May 10, 2024.

Table of Contents

PART I — FINANCIAL INFORMATION
Item 1. Financial Statements.	1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	23
Cautionary and Forward-Looking Statements	23
Organization
Business Plan	23
Recent Events
Results of Operations for the Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023	24
Results of Operations for the Six Months Ended March 31, 2024 Compared to the Six Months Ended March 31, 2023	24
Revenue and Cost of Sales	24
Selling, General and Administrative Expenses	24
Research and development expenses	25
Other Income/(Expenses)	25
Net Income/(Loss)	25
Liquidity and Capital Resources	25
Off-Balance Sheet Arrangements	25
Critical Accounting Estimates	26
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	26
Item 4. Controls and Procedures.	26
Evaluation of Disclosure Controls and Procedures	26
Changes in Internal Control Over Financial Reporting	26
PART II — OTHER INFORMATION
Item 1. Legal Proceedings.	27
Item 1.A Risk Factors.	27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	27
Item 3. Defaults Upon Senior Securities.	27
Item 4. Mine Safety Disclosures.	27
Item 5. Other Information.	27
Item 6. Exhibit and Financial Statement Schedules.	27
SIGNATURES	28

Part I- Financial Information

Item 1. Financial Statements

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2024			September 30, 2023
	Unaudited
ASSETS
CURRENT ASSETS
Cash	$	9,812		$	21,415
Prepaid expenses		75,833			40,833
TOTAL ASSETS	$	85,645		$	62,248
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable	$	636,784		$	514,686
Accrued expenses and other current liabilities		2,642,342			1,982,567
Derivative and warrants liabilities		1,314,660			2,982,382
Due to related parties		181,217			181,217
Short term loans, related parties		34,000			21,000
Convertible promissory notes, net of debt discount and debt issuance costs of $55,670 and $0 respectively		2,118,038			2,166,380
Convertible promissory note related party, net of debt discount and debt issuance cost of $0 and $0, respectively		12,500			12,500
Total Current Liabilities		6,939,541			7,860,732
TOTAL LIABILITIES		6,939,541			7,860,732
SHAREHOLDERS' DEFICIT
Preferred stock 50,000,000 shares authorized, shares issued and outstanding designated as follows: Preferred Stock Series B, $0.01 par value, 25,000 authorized 600 shares issued and outstanding, respectively		6			6
Common stock, no par value; 2,000,000,000 authorized common shares 30,512,014 and 21,744,209 shares issued and outstanding, respectively		43,784,278			43,683,197
Additional paid in capital		5,338,906			5,335,398
Paid in capital, common stock option and warrants		5,367,273			5,338,273
Paid in capital, preferred stock		4,747,108			4,747,108
Accumulated deficit		(66,091,467	)		(66,902,466	)
TOTAL SHAREHOLDERS' DEFICIT		(6,853,896	)		(7,798,484	)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$	85,645		$	62,248

The accompanying notes are an integral part of these consolidated financial statements.

1

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2024 AND 2023

(Unaudited)

	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
SALES	$	-		$	-		$	-		$	-
COST OF GOODS SOLD		-			-			-			-
GROSS PROFIT		-			-			-			-
OPERATING EXPENSES
Research and development expenses		36,275			41,036			85,972			76,000
Selling, general and administrative expenses		196,280			1,013,952			404,129			1,496,106
TOTAL OPERATING EXPENSES		232,555			1,054,988			490,101			1,572,106
LOSS FROM OPERATIONS BEFORE OTHER INCOME/(EXPENSES)		(232,555	)		(1,054,988	)		(490,101	)		(1,572,106	)
OTHER INCOME/(EXPENSES)
Gain (Loss) on change in derivative liability		(125,317	)		1,964,593			1,733,636			(116,991	)
Change in commitment fee guarantee		(28,250	)		(193,625	)		(254,250	)		74,125
Interest expense		(106,472	)		(262,216	)		(178,286	)		(562,670	)
TOTAL OTHER INCOME/(EXPENSES)		(260,039	)		1,508,752			1,301,100			(605,536	)
NET INCOME (LOSS)		(492,594	)		453,764			810,999			(2,177,642	)
Deemed dividend on warrant re-pricing		-			(44,241	)		-			(44,241	)
Net income (loss) attributable to common shareholders		(492,594	)		409,523			810,999			(2,221,883	)
BASIC INCOME (LOSS) PER SHARE	$	(0.02	)	$	0.02		$	0.03		$	(0.11	)
DILUTED INCOME (LOSS) PER SHARE	$	(0.02	)	$	(0.03	)	$	(0.00	)	$	(0.11	)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC		28,310,935			20,698,747			25,828,176			19,832,524
DILUTED		28,310,935			45,601,456			368,598,520			19,832,524

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ DEFICIT

FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023

												Stock
	Preferred Stock,								Additional			Options/ Warrants		Paid in Capital,
	Class B				Common Stock				Paid-in			Paid in		Preferred		Accumulated
	Shares		Amount		Shares		Amount		Capital			Capital		Stock		Deficit			Total
Balance as of September 30, 2022		600	$	6		18,669,507	$	43,225,982	$	5,340,398		$	4,210,960	$	4,747,108	$	(62,177,520	)	$	(4,653,066	)
Common stock issued for services		-		-		1,490,521		259,702		-			-		-		-			259,702
Common stock issued, subscriptions		-		-		525,000		55,000		(5,000	)		-		-		-			50,000
Stock issued as commitment fee on promissory note extension		-		-		500,000		82,500		-			-		-		-			82,500
Stock Compensation - Options		-		-		-		-		-			563,314		-		-			563,314
Warrant expense		-		-		-		-		-			148,500		-		-			148,500
Net Loss		-		-		-		-		-			-		-		(2,177,642	)		(2,177,642	)
Balance as of March 31, 2023 (Unaudited)		600	$	6		21,185,028	$	43,623,184	$	5,335,398		$	4,922,774	$	4,747,108	$	(64,355,162	)	$	(5,726,692	)

											Stock
	Preferred Stock,								Additional		Options/ Warrants		Paid in Capital,
	Class B				Common Stock				Paid-in		Paid in		Preferred		Accumulated
	Shares		Amount		Shares		Amount		Capital		Capital		Stock		Deficit			Total
Balance as of September 30, 2023		600	$	6		21,744,209	$	43,683,197	$	5,335,398	$	5,338,273	$	4,747,108	$	(66,902,466	)	$	(7,798,484	)
Common stock issued for services		-		-		417,504		6,159		-		-		-		-			6,159
Common stock issued on conversion of loans		-		-		8,350,301		94,922		-		-		-		-			94,922
Imputed interest on related party loans		-		-		-		-		3,508		-		-		-			3,508
Warrant expense on loan extension		-		-		-		-		-		29,000		-		-			29,000
Net Income		-		-		-		-		-		-		-		810,999			810,999
Balance as of March 31, 2024 (Unaudited)		600	$	6		30,512,014	$	43,784,278	$	5,338,906	$	5,367,273	$	4,747,108	$	(66,091,467	)	$	(6,853,896	)

FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023

											Stock
	Preferred Stock,								Additional		Options/ Warrants		Paid in Capital,
	Class B				Common Stock				Paid-in		Paid in		Preferred		Accumulated
	Shares		Amount		Shares		Amount		Capital		Capital		Stock		Deficit			Total
Balance as of December 31, 2022 (Unaudited)		600	$	6		20,326,276	$	43,489,152	$	5,335,398	$	4,210,960	$	4,747,108	$	(64,808,926	)	$	(7,026,302	)
Common stock issued for services		-		-		208,752		36,532		-		-		-		-			36,532
Common stock issued, subscriptions		-		-		150,000		15,000		-		-		-		-			15,000
Stock issued as commitment fee on promissory note extension		-		-		500,000		82,500		-		-		-		-			82,500
Stock Compensation - Options		-		-		-		-		-		563,314		-		-			563,314
Warrant expense		-		-		-		-		-		148,500		-		-			148,500
Net Loss		-		-		-		-		-		-		-		453,764			453,764
Balance as of March 31, 2023 (Unaudited)		600	$	6		21,185,028	$	43,623,184	$	5,335,398	$	4,922,774	$	4,747,108	$	(64,355,162	)	$	(5,726,692	)

											Stock
	Preferred Stock,								Additional		Options/ Warrants		Paid in Capital,
	Class B				Common Stock				Paid-in		Paid in		Preferred		Accumulated
	Shares		Amount		Shares		Amount		Capital		Capital		Stock		Deficit			Total
Balance as of December 31, 2023 (Unaudited)		600	$	6		23,955,540	$	43,717,268	$	5,338,042	$	5,367,273	$	4,747,108	$	(65,598,873	)	$	(6,429,176	)
Common stock issued for services		-		-		208,752		2,088		-		-		-		-			2,088
Common stock issued on conversion of loans		-		-		6,347,722		64,922		-		-		-		-			64,922
Imputed interest on related party loans		-		-		-		-		864		-		-		-			864
Net Income		-		-		-		-		-		-		-		(492,594	)		(492,594	)
Balance as of March 31, 2024 (Unaudited)		600	$	6		30,512,014	$	43,784,278	$	5,338,906	$	5,367,273	$	4,747,108	$	(66,091,467	)	$	(6,853,896	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

NOVACCESS GLOBAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023

(Unaudited)

	For the Six Months Ended
	March 31, 2024			March 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	810,999		$	(2,177,642	)
Adjustment to reconcile net income/(loss) to net cash used in operating activities
Amortization of debt discount and debt issuance costs recorded as interest expense		31,522			432,083
Loss (Gain) on change in derivative liability		(1,733,636	)		116,991
Warrants issued for loan extension		29,000			-
Imputed interest on related party loan		3,508			-
Stock issued and issuable for services		6,159			259,702
Stock based compensation		-			711,814
Fair value of commitment shares issued for loans		-			82,500
Changes in Assets and Liabilities:
Prepaid expenses		(35,000	)		(20,818	)
Accounts payable		126,570			71,147
Accrued expenses and interest on notes payable		659,775			167,713
NET CASH USED IN OPERATING ACTIVITIES		(101,103	)		(356,510	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock subscriptions received		-			50,000
Proceeds from short term loans related parties		13,000			8,500
Proceeds from convertible notes payable		76,500			340,000
Payments to related party for redemption of preferred stock		-			(5,000	)
Principal payments on convertible debt		-			(79,250	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		89,500			314,250
CASH FLOWS FROM INVESTING ACTIVITIES:
NET CASH USED BY INVESTING ACTIVITIES		-			-
NET INCREASE (DECREASE) IN CASH		(11,603	)		(42,260	)
CASH, BEGINNING OF PERIOD		21,415			64,251
CASH, END OF PERIOD	$	9,812		$	21,991
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	$	-		$	17,711
Taxes paid	$	-		$	800
SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS
Common stock issued on conversion of convertible note	$	94,922		$	-
Initial derivative recognition on new loans and warrants	$	65,914		$	370,209

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

NOVACCESS GLOBAL INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS- UNAUDITED

MARCH 31, 2024 AND 2023

1. ORGANIZATION AND LINE OF BUSINESS

Organization

NovAccess Global Inc. (“NovAccess” or the “Company”) is a Colorado corporation formerly known as Sun River Mining Inc. and XsunX, Inc. The Company was originally incorporated in Colorado on February 25, 1997. Effective September 24, 2003, the Company completed a plan of reorganization and name change to XsunX, Inc. Effective August 25, 2020, we filed articles of amendment to our articles of incorporation with the Colorado Secretary of State to: effectuate a 1-for-1,000 reverse stock split of the Company’s outstanding shares of common stock; and change the name of the Company to “NovAccess Global Inc.” After completing the acquisition of StemVax LLC in September 2020, we exited the solar business and focused all our efforts on our biopharmaceutical business.

Line of Business

NovAccess Global Inc. is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We specialize in cutting-edge research related to utilizing a patient’s own immune system to attack the cancer. We are filing an Investigational New Drug Application (IND) and working closely with the Food and Drug Administration (FDA) to obtain approval for human clinical trials to determine the safety and efficacy of our drug product for brain cancer patients. Once we have successfully completed the clinical trials and proven that the new therapy is safe and efficacious, we plan to commercialize the product. We also have expertise in successfully executing clinical trials, bringing products to market and increasing the market size of products through our advisory board. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecules development, gene therapy and other technical assays needed for protein and genetic analysis of cancer cells.

NovAccess operates as a research and development (R&D) company out of Ohio and California, and our executive management and scientific advisory board provide over 15 years of extensive experience in all aspects of biopharmaceutical R&D and commercialization of drug candidates.

Going Concern

The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company does not generate significant revenue, and has negative cash flows from operations, which raises substantial doubt about the Company’s ability to continue as a going concern.

The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusions. The Company has obtained funds from its shareholders and from lenders since its inception through the period ended March 31, 2024. Management believes the existing shareholders, prospective new investors and lenders will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the development of its business.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of NovAccess Global Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Basis of Presentation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary StemVax, LLC. All significant inter-company accounts and transactions between these entities have been eliminated in these consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, warrants, and derivative liabilities. Actual results could differ from those estimates.

5

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Cash and Cash Equivalents

For purposes of the statements of cash flows, cash and cash equivalents include cash in banks and money markets with an original maturity of three months or less.

Stock-Based Compensation

Share-based Payment applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. We are required to follow a fair value approach using an option-pricing model, such as the Binomial lattice valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. This has not had a material impact on our results of operations.

Net Earnings (Loss) per Share Calculations

Net earnings (loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings (loss) per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the period.

The computation of diluted net earnings (loss) per share is similar to the computation of basic net earnings (loss) per share except that the numerator may have to adjust for income or loss associated with potentially dilutive securities that are assumed to have resulted in the issuance of shares of common stock, and the denominator may have to adjust to include the number of additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued during the period to reflect the potential dilution that could occur from shares of common stock issuable through stock options, warrants or convertible preferred stock. For purposes of determining diluted earnings per common share, the treasury stock method is used for stock options and warrants, and the if-converted method is used for convertible preferred stock as prescribed in ASC Topic 260.

	For the Three Months Ended						For the Six Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Basic net income (loss) per share:
Numerator:
Net income (loss)	$	(492,594	)	$	409,523		$	810,999		$	(2,221,883	)
Denominator:
Weighted average number of common shares outstanding		28,310,935			20,698,747			25,828,176			19,832,524
Net income (loss) per share	$	(0.02	)	$	0.02		$	0.03		$	(0.11	)
Diluted net income (loss) per share:
Numerator:
Net income (loss)	$	(492,594	)	$	409,523		$	810,999		$	(2,221,883	)
Interest and issuance cost accretion		-			240,190			156,075			-
Gain on change of derivative liability		-			(1,964,593	)		(1,733,636	)		-
Net income (loss) per share, diluted	$	492,594		$	(1,314,880	)	$	(766,562	)	$	(2,221,883	)
Denominator:
Weighted average number of common shares outstanding		28,310,935			20,698,747			25,828,176			19,832,524
Preferred shares converted to common shares		-			6,000,000			6,000,000			-
Options to purchase common stock		-			1,885,714			-			-
Warrants to purchase common shares		-			942,857			-			-
Potential shares issuable on convertible debt		-			16,074,138			336,770,344			-
Weighted average number of common shares outstanding, diluted		28,310,935			45,601,456			368,598,520			19,832,524
Net income (loss) per share, diluted	$	(0.02	)	$	(0.03	)	$	(0.00	)	$	(0.11	)

6

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

In addition, the following securities were not included in the computation of diluted share for the quarters and six months ended March 31, 2024 and 2023, because they were antidilutive, but could potentially dilute earnings per share in the future:

	For the three months ended				For the Six months ended
	March 31,				March 31,
	2024		2023		2024		2023
Preferred shares converted to common shares		6,000,000		-		-		6,000,000
Options to purchase common stock		-		-		-		1,885,714
Warrants to purchase common shares		-		-		-		942,857
Potential shares issuable on convertible debt		339,274,373		-		-		15,331,134
Total shares excluded from diluted EPS calculation		345,274,373		-		-		24,159,705

Fair Value of Financial Instruments

Fair Value of Financial Instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2024, the balances reported for cash, prepaid expenses, accounts payable, accrued expenses approximate the fair value because of their short maturities.

We adopted Accounting Standards Codification (“ASC”) Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

7

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments (continued)

We measure certain financial instruments at fair value on a recurring basis. The Company had no assets that are required to be valued on a recurring basis as of March 31, 2024, and September 30, 2023. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at March 31, 2024, and September 30, 2023:

	Total		(Level 1)		(Level 2)		(Level 3)
Assets:	$	-	$	-	$	-	$	-
Liabilities:
Derivative Liability at fair value as of September 30, 2023	$	2,253,391	$	-	$	-	$	2,253,391
Derivative Liability warrants at fair value as of September 30, 2023		728,991		-		-		728,991
Total Derivative Liability as of September 30, 2023	$	2,982,382	$	-	$	-	$	2,982,382
Derivative Liability at fair value as of March 31, 2024	$	1,248,595		-		-	$	1,248,595
Derivative Liability warrants at fair value as of March 31, 2024		66,065		-		-		66,065
Total Derivative Liability as of March 31, 2024	$	1,314,660		-		-	$	1,314,660

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

	Derivative Liability Promissory Notes			Derivative Liability Warrants			Total Derivative Liability
Balance as of September 30, 2022	$	1,207,403		$	232,609		$	1,440,012
Fiscal year 2023 initial derivative liabilities		480,958			332,753			813,711
Net loss on change in fair value of derivative liability		802,495			163,629			966,124
Extinguishment of derivative		(237,465	)		-			(237,465	)
Ending balance as of September 30, 2023	$	2,253,391		$	728,991		$	2,982,382
Initial recognition of new loans		65,914			-			65,914
Net gain on change in fair value of derivative liability		(1,070,710	)		(662,926	)		(1,733,636	)
Ending balance as of March 31, 2024	$	1,248,595		$	66,065		$	1,314,660

8

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recent Accounting Pronouncements

In July 2023, the SEC adopted the final rule under SEC Release No. 33-11216, Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure, requiring disclosure of material cybersecurity incidents on Form 8-K and periodic disclosure of a registrant’s cybersecurity risk management, strategy and governance in annual reports. Regulation S-K Item 6 disclosure requirements under this rule will be effective for our fiscal year ending on September 30, 2024. Incident disclosure requirements in Form 8-K will be effective for us on March 15, 2024. The Company has adopted this final rule and it did not have an impact on the Company’s consolidated finance statement disclosures.

In October 2023, the FASB issued Accounting Standards Update (ASU) 2023-06, which incorporates 14 of the 27 disclosures referred to by the SEC in their SEC Release No. 33-10532, Disclosure Update and Simplification, issued on August 17, 2018. The amendments in this ASU modify the disclosure or presentation requirements of a variety of Topics in the Codification and apply to all reporting entities within the scope of the affected Topics unless otherwise indicated. The amendments in this ASU should be applied prospectively. For public business entities, the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company has evaluated the effects of the adoption of ASU No. 2022-03, and it is not expected to have an impact on the Company’s consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which amends and enhances the disclosure requirements for reportable segments. All disclosure requirements under this standard will also be required for public entities with a single reportable segment. The new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of adopting this standard on the Company’s Consolidated Financial Statements.

In December 2023, the FASB issued ASU No. 2023-08, “Accounting for and Disclosure of Crypto Assets”, which amends and enhances the disclosure requirements for crypto assets. The new requirements will be effective for public business entities for fiscal periods beginning after December 15, 2024. The Company has evaluated the effects of the adoption of ASU No. 2022-08, and it is not expected to have an impact on the Company’s Consolidated Financial Statements

In December 2023, the FASB issued ASU No. 2023-09, “Improvements to Income Tax Disclosures”, which requires companies to provide disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirements will be effective for public business entities for fiscal periods beginning after December 15, 2024. The Company is currently assessing the impact of adopting this standard on the Company’s Consolidated Financial Statements.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted would have a material effect on the accompanying financial statements.

3. CAPITAL STOCK

As of March 31, 2024, the Company’s authorized stock consisted of 2,000,000,000 shares of common stock, with no par value.

The Company is also authorized to issue 50,000,000 shares of preferred stock with a par value of $0.01 per share. The rights, preferences and privileges of the holders of the preferred stock are determined by the Board of Directors prior to issuance of such shares.

Preferred Stock

As of March 31, 2024, the Company had 600 shares of issued and outstanding Series B Preferred held by Irvin Consulting LLC, a company owned by Dwain Irvin, the CEO of the Company.

Each share of outstanding Series B Preferred Stock entitles the holder to cast 40,000 votes. Each share of Series B Preferred Stock is convertible at the option of the holder into 10,000 common shares. In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Company, the holders of shares of Series B Preferred Stock shall be paid out based on an as converted basis. Dividends for Series B Preferred Stock shall be declared on an as converted basis.

9

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

3. CAPITAL STOCK (Continued)

Common Stock

During the six months ended March 31, 2024, the Company issued 8,767,805 shares of common stock.

The Company issued 8,350,301 shares on the conversion of the April 11, 2023 Note and the April 24, 2023 Note representing principal of $79,250 plus interest of $4,472, and principal of $11,200 respectively. The debt was converted within the terms of the agreements (as discussed below in Note 4).

The Company issued 417,504 shares to various vendors for services provided for a value of $6,159 recorded at fair value of shares on the respective grant dates and including 217,500 shares issued to a related party for services provided amounting to $3,208 recorded at the fair value of shares on the respective grant dates.

During the six months ended March 31, 2023, the Company issued 2,515,521 shares of common stock. 1,490,521 shares were issued to various vendors for services provided including 217,500 shares issued to a related party for services provided; 525,000 shares were issued in relation to stock subscriptions; and 500,000 shares were issued as commitment fees in connection with the letter agreement issued on February 9, 2023.

4. CONVERTIBLE PROMISSORY NOTES

Convertible Promissory notes as on March 31, 2024	Principal Amount		Unamortized balance of Debt Discount			Outstanding balance as on March 31, 2024		Derivative balance as on March 31, 2024
2013 Note	$	12,000	$	-		$	12,000	$	-
2014 Note		50,880		-			50,880		134,334
2017 Note		115,000		-			115,000		283,699
February 2022 Note		250,000		-			250,000		95,363
May 2022 Note		1,000,000		-			1,000,000		402,643
August 2022 Note		100,000		-			100,000		-
February 2023 Note		265,000		-			265,000		100,086
April 24, 2023 Note		43,050		-			43,050		32,537
June 19, 2023 Note		75,000		-			75,000		28,397
June 20, 2023 Note		55,000		-			55,000		43,074
August 16, 2023 Note		55,000		-			55,000		44,905
August 17, 2023 Note		55,000		-			55,000		44,660
December 29, 2023 Note		29,444		-			29,444		10,166
February 27, 2024 Note		68,334		(55,670	)		12,664		28,731
Total		2,173,708		(55,670	)		2,118,038		1,248,595

2013 Note

On October 1, 2013, the Company issued an unsecured convertible promissory note (the “2013 Note”) in the amount of $12,000 to a former Board member (the “Holder”) in exchange for retention as a director during the fiscal year ending September 30, 2014. The Note can be converted into shares of common stock by the Holder for $4.50 per share. The Note matured on October 1, 2015, and bore a one-time interest charge of $1,200 which was applied to the principal on October 1, 2014. As of March 31, 2024, the outstanding principal balance was $12,000 and accrued interest was $1,200. This loan is in default.

10

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

2014 Note

On November 20, 2014, the Company issued a 10% unsecured convertible promissory note (the “2014 Note”) for the principal sum of up to $400,000 plus accrued interest on any advanced principal funds. The 2014 Note matured eighteen months from each advance. The 2014 Note may be converted by the lender into shares of common stock of the Company at the lesser of $12.50 per share or (b) fifty percent (50%) of the lowest traded prices following issuance of the 2014 Note or (c) the lowest effective price per share granted to any person or entity. On November 20, 2014, the lender advanced $50,000 to the Company under the 2014 Note at inception. On various dates from February 18, 2015, through September 30, 2016, the lender advanced an additional $350,000 under the 2014 Note. During the period ended June 30, 2023, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2024. As of March 31, 2024, the outstanding principal balance was $50,880 and accrued interest was $39,254.

2017 Note

On May 10, 2017, the Company issued a 10% unsecured convertible promissory note (the “2017 Note”) for the principal sum of up to $150,000 plus accrued interest on any advanced principal funds. The Company received a tranche in the amount of $25,000 upon execution of the 2017 Note. On various dates, the Company received additional tranches in the aggregate sum of $90,000. During the period ended June 30, 2023, the Company and lender agreed to extend the maturity date for the outstanding balance to June 30, 2024. The 2017 Note may be converted by the lender into shares of common stock of the Company at the lesser of $10 per share or (b) fifty percent (50%) of the lowest traded price of common stock recorded on any trade day after the effective date, or (c) the lowest effective price per share granted to any person or entity. As of March 31, 2024, the outstanding principal balance was $115,000 and accrued interest was $75,353.

August 2021 Note

On August 20, 2021, the Company issued a 10% secured promissory note (the “August 2021 Note”) for the principal sum of $500,000 plus accrued interest. The August 2021 Note was to mature on February 20, 2022, unless extended for up to an additional six months. The August 2021 Note could be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of 90% (representing a 10% discount) multiplied by the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period. The Company issued 1,000,000 warrants at a price of $1.50 in connection with the note and issued 400,000 shares as a commitment fee. In February 2022, the Company extended the term of the August 2021 Note for an additional six months. The Company repaid the August 2021 Note on May 9, 2022, in connection with the issuance of the May 2022 Note described below. As of March 31, 2024, the balance on the August 2021 Note was $0.

In connection with the February 2023 Letter Agreement (described below) the warrants issued in connection with this note were repriced to $0.20 per share. The warrants contained a ratchet price adjustment provision and the difference in fair value upon the reduction of exercise price was treated as a deemed dividend for the down round adjustment provision.

February 2022 Note

On February 15, 2022, the Company issued a 10% secured promissory note (the “February 2022 Note”) for the principal sum of $250,000 plus accrued interest. The February 2022 Note was to mature on August 15, 2022, unless extended for up to an additional six months. The February 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before the conversion. In July 2022, the Company extended the term of the February 2022 note for another six months until February 15, 2023. In connection with the note, the Company issued 500,000 warrants with an exercise price of $1.50. The February 2022 Note had an original issuance discount amounting to $25,000, debt issuance cost amounting to $12,000 and the Company issued 300,000 shares as a commitment fee valued at $111,000 based on the share price on the date of the agreement. The initial recognition of derivative and warrant liability was recorded as debt discount and amortized over the term of the loan. The debt discount is fully amortized and the balance in debt discount as on March 31, 2024, was $0. As of March 31, 2024, the principal balance outstanding was $250,000 and accrued interest was $31,250.

11

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

On February 9, 2023, the Company entered into a letter agreement in connection with the February 2022 Note, whereby the lender extended the due date of the loan to May 9, 2023, and deferred all interest payments for the period from January 1, 2023, until May 9, 2023. Pursuant to the letter agreement the exercise price of the warrants issued with the February 2022 Note was reduced to $0.20 per share. The warrants contained a ratchet price adjustment provision and the difference in fair value upon the reduction of exercise price was treated as a deemed dividend for the down round adjustment provision.

On June 8, 2023, the Company entered into a further letter agreement which extended the due date of the note until June 30, 2023. On August 8, 2023, the Company entered into a further letter agreement extending the due date of the loan until August 31, 2023. On January 29, 2024, the Holder agreed to a further extension until February 29, 2024, and on May 13, 2024, to a further extension until May 31, 2024.

May 2022 Note

On May 5, 2022, the Company issued a 12% secured promissory note (the “May 2022 Note”) for the principal sum of $1,000,000 plus accrued interest. The May 2022 Note was to mature on November 5, 2022, unless extended for up to an additional six months. If extended, the interest rate increased to 15% for the remaining six months. The May 2022 Note may be converted, only following an event of default, by the lender into shares of common stock of the Company at the lesser of the lowest trading price during the previous twenty (20) trading day period ending on the issuance date, or during the previous twenty (20) trading day period before conversion. The Company used some of the proceeds from the May 2022 Note to pay off the August 2021 Note. In November 2022, the Company extended the May 2022 Note for another six months until May 5, 2023. In connection with the loan the Company issued 1,000,000 warrants at an exercise price of $0.01. The May 2022 Note had an original issuance discount amounting to $100,000, debt issuance costs of $25,500 and the Company issued 875,000 shares as a commitment fee valued at $259,875 based on the share price on the date of the agreement. The initial recognition of derivative liability of $412,065 and warrant liability amounting to $282,051 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2024, was $0. As of March 31, 2024, the principal balance outstanding was $1,000,000 and the accrued interest was $187,500.

On February 9, 2023, the Company entered into a letter agreement in connection with the May 2022 Note deferring all interest payments from January 1, 2023, until May 9, 2023.

On June 8, 2023, the Company entered into a further letter agreement which extended the due date of the of the note until June 30, 2023. On August 8, 2023, the Company entered into a further letter agreement extending the due date of the loan until August 31, 2023. On January 29, 2024, the Holder agreed to a further extension until February 29, 2024, and on May 13, 2024, to a further extension until May 31, 2024,

August 2022 Note

On August 8, 2022, the Company issued a 12% unsecured promissory note (the “August 2022 Note”) for the principal sum of $100,000 plus accrued interest. The August 2022 Note matured on August 8, 2023. The holder has the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a conversion price of $0.15. The initial recognition of derivative liability of $77,259 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2024, was $0. As of March 31, 2024, the balance outstanding was $100,000 and accrued interest was $27,068.

On August 3, 2023, the Company and the holder signed an agreement extending the loan until November 8, 2023, with an interest rate of 14% commencing on August 9, 2023. On January 31, 2024, the Holder agreed to a further extension until February 29, 2024, in return for an additional fee of $5,000. On May 9, 2024, the Holder agreed to a third extension until August 10, 2024, in exchange for an interest rate change to 20% retroactive to August 9, 2022. The catch-up interest expense impact to the Company financials will be about $5,000.

12

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

September 2022 Note

On September 22, 2022, the Company issued an 8% secured promissory note (the “September 2022 Note”) for the principal sum of $79,250 plus accrued interest. The September 2022 Note was to mature on September 22, 2023. In case of default in repayment of the outstanding amount on the due date, the balance would have borne interest of 22% per annum. The holder had the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company had the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty was subject to agreement between the parties. The initial recognition of derivative liability amounting to $75,000 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The Company repaid the loan in full including interest of $3,127 and prepayment penalty of $20,594 on March 12, 2023. As of March 31, 2024, the balance outstanding was $0.

November 2022 Note

On November 1, 2022, the Company issued an 8% secured promissory note (the “November 2022 Note”) for the principal sum of $55,000 plus accrued interest. The November 2022 Note was to mature on November 1, 2023. In case of default in repayment of the outstanding amount on the due date, the balance would have borne interest of 22% per annum. The holder had the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company had the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty was subject to agreement between the parties. The initial recognition of derivative liability amounting to $50,750 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. The Company repaid the loan in full including interest of $2,109 and prepayment penalty of $14,277 on April 24, 2023. As of March 31, 2024, the balance outstanding was $0.

December 2022 Note

On December 7, 2022, the Company issued an 8% secured promissory note (the “December 2022 Note”) for the principal sum of $55,000 plus accrued interest. The December 2022 Note was to mature on December 7, 2023. In case of default in repayment of the outstanding amount on the due date, the balance would have borne interest of 22% per annum. The holder had the right, after six months, until the date of payment in full of all amounts outstanding, to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the Common Stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company had the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty was subject to agreement between the parties. The initial recognition of derivative liability amounting to $50,750 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. On June 13, 2023, the lender converted $12,000 of the amount due into 141,677 shares of the Company and on June 20, 2023, the Company repaid the balance of the loan together with $2,260 in interest and $11,315 in prepayment penalty. As of March 31, 2024, the balance outstanding was $0.

13

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

February 2023 Letter Agreement

On February 9, 2023, the Company entered into a letter agreement, whereby the Company borrowed an additional loan amounting to $265,000, which was added to the May 2022 Note. The $265,000 loan has an original issuance discount of 10% of the principal and bears interest at 10% a year. This loan was due on May 9, 2023. Our chief executive officer, Dwain K. Irvin, guaranteed repayment of the loan. Pursuant to this agreement, the Company paid a commitment fee of 500,000 unregistered shares of the Company’s common stock which were valued at $82,500 based on the share price on the date of the agreement. The initial recognition of derivative liability amounting to $110,576 was recorded as debt discount and amortized over the term of the loan. The original issuance discount of $26,500 was recorded as debt discount and amortized over the term of the loan. As of March 31, 2024, the unamortized debt discount balance was $0, the principal balance outstanding was $265,000 and accrued interest was $30,181.

Also, as part of this agreement the lender extended the term of February 2022 note to May 9, 2023, and deferred payment of all interest due on both the February 2022 note and May 2022 note until May 9, 2023. In addition, the Company issued 1,000,000 warrants to purchase common stock at a price of $0.20 per share and repriced the warrants issued in connection with the August 2021 Note and February 2022 Note to $0.20 per share. Since the consideration was for all the modifications and not just the additional loan, the expense was recorded immediately.

On June 8, 2023, the Company entered into a letter agreement which extended the due date of the February 22 note until June 30, 2023. On August 8, 2023, the Company entered into a further letter agreement extending the due date of the loan until August 31, 2023. On January 29, 2024, the Holder agreed to a further extension until February 29, 2024, and on May 13, 2024, agreed to a further extension until May 31, 2024.

April 11, 2023 Note

On April 11, 2023, the Company issued a convertible promissory note for the principal sum of $79,250 plus accrued interest (the “April 11, 2023 Note”). The loan bears interest at 8% a year. The note matures on April 11, 2024. In case of default in repayment of the outstanding amount on the due date, the balance will bear interest of 22% per annum. The holder has the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the common stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company has the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty is subject to agreement between the parties. The initial recognition of the derivative liability of $75,000 was recorded in debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. As of September 30, 2023, the remaining debt discount and debt issuance cost balance was expensed since the loan was in default because of a delay in filing the Company’s report on Form 10-K for the period ending September 30, 2023. During the six months ending March 31, 2024, on various dates the $79,250 principal of the loan and accrued interest was converted to 6,953,792 common shares within the terms of the note with no gain or loss. As of March 31, 2024, the principal balance outstanding was $0, and the accrued interest was $0.

April 24, 2023 Note

On April 24, 2023, the Company issued a convertible promissory note in the original principal amount of $54,250 plus accrued interest (the “April 24, 2023 Note”). The loan bears interest at 8% a year. The note matures on April 24, 2024. In case of default in repayment of the outstanding amount on the due date the balance will bear interest of 22% per annum. The holder has the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the common stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company has the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty is subject to agreement between the parties. The initial recognition of derivative liability amounting to $50,000 was recorded as debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded as debt discount and amortized over the term of the loan. As of September 30, 2023, the remaining balance in debt discount and debt issuance costs was expensed since the loan was in default because of a delay in filing the Company’s report on Form 10-K for the period ending September 30, 2023. On March 14, 2024, $11,200 of the loan was converted to 1,396,509 common shares within the terms of the note with no gain or loss. As of March 31, 2024, the principal balance outstanding was $43,050 and the accrued interest was $3,977. 

14

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

June 19, 2023 Letter Agreement

On June 19, 2023, the Company entered into a letter agreement whereby it borrowed a further $75,000 which was added to the May 2022 Note. This loan bears interest at 15% a year and originally matured on July 16, 2023. Our chief executive officer, Dwain K. Irvin, guaranteed repayment of the $75,000 loan. In connection with this loan the Company issued 750,000 warrants at an exercise price of $0.0001 per share. The initial recognition of the derivative liability was $75,000 which is amortized over the life of the loan. As of March 31, 2024, the principal balance outstanding was $75,000 and accrued interest was $8,750.

On August 8, 2023, the Company entered into a further letter agreement extending the due date of the loan until August 31, 2023. On January 31, 2024, the Holder agreed to a further extension until February 29, 2024, and on May 13, 2024, agreed to a further extension until May 31, 2024.

June 20, 2023 Note

On June 20, 2023, The Company issued a convertible promissory note in the original principal amount of $55,000 plus accrued interest (the “June 20, 2023 Note”). The loan bears interest at 8% a year and matures on June 20, 2024. In case of default in repayment of the outstanding amount on the due date, the balance will bear interest of 22% per annum. The holder has the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the common stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company has the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty is subject to agreement between the parties. The initial recognition of the derivative liability of $17,937 was recorded in debt discount and amortized over the term of the loan. The debt issuance cost of $4,250 was recorded in debt discount and amortized of the term of the loan. As of September 30, 2023, the remaining balance in debt discount and debt issuance cost was expensed since the loan was in default because of a delay in filing the Company’s report on Form 10-K for the period ending September 30, 2023. As of March 31, 2024, the principal balance outstanding was $55,000 and accrued interest was $3,375. The note is no longer in default.

August 16, 2023 Note

On August 16, 2023, the Company issued a convertible promissory note in the original principal amount of $55,000 plus accrued interest (the “August 16, 2023, Note”). The note bears interest at 8% a year and matures on August 16, 2024. In case of default in repayment of the outstanding amount on the due date, the balance will bear interest of 22% per annum. The holder has the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the common stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company has the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty is subject to agreement between the parties. The initial recognition of the derivative liability of $52,800 was recorded in debt discount and amortized over the term of the loan. The debt issuance cost of $2,200 was recorded in debt discount and amortized of the term of the loan. As of September 30, 2023, the remaining balance in debt discount and debt issuance cost was expensed since the loan was in default as a result of a delay in filing the Company’s report on Form 10-K for the period ending September 30, 2023. As of March 31, 2024, the principal balance outstanding was $55,000 and accrued interest was $2,748. The loan is no longer in default.

15

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

August 17, 2023 Note

On August 17, 2023, the Company issued a convertible promissory note in the original principal amount of $55,000 plus accrued interest (the “August 17, 2023 Note”). The note bears interest at 8% a year and matures on August 17, 2024. In case of default in repayment of the outstanding amount on the due date, the balance will bear interest of 22% per annum. The holder has the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to 65% multiplied by the market price. Market price means the average of the three lowest trading prices for the common stock during the fifteen-trading day period ending on the latest complete trading day prior to the conversion date. The Company has the right to prepay the loan with a prepayment penalty of between 15% and 25% of the total amount owed in the first six months. Thereafter, any prepayment penalty is subject to agreement between the parties. The initial recognition of the derivative liability of $50,000 was recorded in debt discount and amortized over the term of the loan. The debt issuance cost of $5,000 was recorded in debt discount and amortized of the term of the loan. As of September 30, 2023, the remaining balance in debt discount and debt issuance cost was expensed since the loan was in default as a result of a delay in filing the Company’s report on Form 10-K for the period ending September 30, 2023. As of March 31, 2024, the principal balance outstanding was $55,000 and accrued interest was $2,736. The loan is no longer in default.

December 29, 2023 Letter Agreement

On December 29, 2023, the Company entered into a letter agreement with the holder of the February 2022 Note. Under this agreement the holder agreed to loan the Company an additional $29,444 to be added to the principal of the February 2022 Note. An initial amount of $10,000 was loaned on December 29, 2023, with the remaining amount of $19,444 loaned to the Company on February 8, 2024. The loan has an original interest discount of 10% and bears interest at 10% per annum. As of March 31, 2024, the principal balance outstanding was $29,444 and accrued interest was $537. On May 13, 2024, the Holder agreed to a further extension until May 31, 2024.

As part of this agreement, the Company agreed to extend the life on each of the warrants previously issued to the holder by two years.

February 27, 2024 Note

On February 27, 2024, the Company issued a convertible promissory note in the principal amount up to $100,000 plus accrued interest (the “February 27, 2024 Note”). The note has an original interest discount of 20%, bears interest at 12% per calendar year and matures on August 27, 2024. The terms of the note included payment in three tranches on February 27, 2024, March 15, 2024, and April 15, 2024.In case of default in repayment of the outstanding amount on the due date, the balance will bear interest of 18% per annum. The holder has the right, after six months, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at a variable conversion price equal to the lowest trading price for the common stock during the twenty-trading day period ending on the latest complete trading day prior to the conversion date. The initial recognition of the derivative liability of $47,293 was recorded in debt discount and will be amortized over the term of the loan. The debt issuance cost of $5,000 was recorded in debt issuance discount and will be amortized over the term of the loan. As of March 31, 2024, the principal balance outstanding was $68,334 and accrued interest was $572.

Evaluation of Financing Transactions

We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The notes have no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the notes under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the notes in their entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically according to the stock price fluctuations based upon the Binomial lattice model calculation.

16

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

4. CONVERTIBLE PROMISSORY NOTES (Continued)

The convertible notes issued and described in this Note do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as a derivative liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

We record the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the notes.

For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

Risk free interest rate	Between 5.4% and 5.5%
Stock volatility factor	Between 97% and 128%
Years to Maturity	Between 1 months and 5 months
Expected dividend yield	None

5. CONVERTIBLE PROMISSORY NOTES, RELATED PARTY

July 2022 Note, related party

On July 28, 2022, the Company issued a 12% unsecured promissory note (the “July 2022 Note”) for the principal sum of $12,500 plus accrued interest. All amounts outstanding under the July 2022 Note were payable on the earlier of: (a) October 31, 2022, or (b) the receipt by the Company of debt or equity financing of $3.0 million. In November 2022, the holder agreed to extend the term of the note until April 2023 and in April 2023 agreed to a further extension until August 31, 2023. The holder has the right, until the date of payment in full of all amounts outstanding to convert unpaid principal and interest and any other amounts into fully paid shares of common stock of the Company at conversion price of $0.15. The initial recognition of derivative liability of $12,500 was recorded as debt discount and amortized over the term of the loan. The balance in debt discount as on March 31, 2024, was $0. As of March 31, 2024, the balance outstanding net of debt discount was $12,500 and accrued interest was $2,508. On January 3, 2024, the holder agreed to a further extension until January 31, 2024, and on January 31, 2024, to an extension until February 29, 2024, and on April 23, 2024, agreed to a further extension until June 15, 2024.

6. SHORT TERM LOANS, RELATED PARTIES

On July 28, 2022, the Company entered into a short-term interest free loan agreement amounting to $12,500, with Jason M. Anderson, an independent member of our board of directors, to fund operations until longer term financing can be obtained by the Company. The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3.0 million.

On February 9, 2023, the Company entered into a second interest-free loan agreement with Mr. Anderson amounting to $8,500. The loan does not bear interest (except on default) and was due on the earlier of August 31, 2023, or our receipt of debt or equity financing of at least $3.0 million.

On January 26, 2024, Jason Anderson loaned the Company a further $2,000 to address short-term cash needs. The loan is non-interest bearing and has the same terms as Mr. Anderson’s previous loans discussed above.

Mr. Anderson has agreed to various extensions on these loans, the most recent being on April 23, 2024, extending the due date until June 15, 2024.

On December 21, 2023, our Chairman, John A. Cassarini loaned the Company $10,000 to address short-term cash need. Our Chief Financial Officer, Neil J. Laird loaned the Company $1,000. These loans do not bear interest and do not have a specified due date but are expected to be paid in full upon completion of the Sumner transaction or other financing.

For the six months ended March 31, 2024, imputed interest of $3,508 on these related party loans was charged to interest expense and credited to additional paid-in capital.

17

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

7. WARRANTS

On August 20, 2021, for value received in connection with the August 2021 Note, the Company issued 1,000,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share. On December 29, 2023, in connection with the letter agreement discussed above, the life of this warrant was extended by two years.

On February 16, 2022, for value received in connection with the February 2022 Note, the Company issued 500,000 warrants to the lender with an exercise price of $1.50 per share with a five-year exercise period. On February 9, 2023, the Company entered into a letter agreement in connection with the August 2021 Note, whereby the exercise price of the warrants issued on the August 2021 Note was reduced to $0.20 per share. On December 29, 2023, in connection with the letter agreement discussed above, the life of this warrant was extended by two years.

Per guidance in ASC 260, the Company determined that the repricing of warrants discussed above, was an exchange of the existing 1,500,000 warrants and the difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was as a deemed dividend. The difference between the fair value of the warrants immediately prior to modification of terms and immediately after the adjustment was calculated as $44,241, using a Black Scholes model based on the following significant inputs: On February 9, 2023:

Common stock price	$0.165
Risk free interest rate	Between 3.8% and 3.7%
Stock volatility factor	Between 156% and 159%
Years to Maturity	Between 3.2 and 4.1 years
Expected dividend yield	None

On May 10, 2022, for value received in connection with the issuance of the May 2022 Note, the Company issued 1,000,000 warrants to the lender with an exercise price of $0.01 per share with a five-year exercise period. On December 29, 2023, in connection with the letter agreement discussed above, the life of this warrant was extended by two years.

On February 9, 2023, for value received in connection with the issuance of the February 2023 Note and extending the payment terms on previously issued notes, the Company issued 1,000,000 warrants to the lender with an exercise price of $0.20 per share with a five-year exercise period. The fair value of the warrant issued in relation to the letter agreement issued in February 2023, was recorded as stock compensation expense amounting to $148,500. On December 29, 2023, in connection with the letter agreement discussed above, the life of this warrant was extended by two years.

In connection with a letter agreement on June 8, 2023, to extend the due date of the February 2022 Note, the May 2022 Note and the February 2023 letter agreement until June 30, 2023, the Company issued common stock purchase warrants at $0.20 a share with a five-year term. 1,000,000 warrants were issued on June 8, 2023, 500,000 warrants were issued on June 15, 2023, and 500,000 warrants were issued on June 30, 2023. The fair value of the warrant issued in relation to the letter agreement issued on June 2023, was recorded as expense amounting to $238,412. On December 29, 2023, in connection with the letter agreement discussed above, the life of this warrant was extended by two years.

On June 19, 2023, for value received in connection with the issuance of the June 20, 2023, letter agreement, the Company issued a warrant to purchase 750,000 shares of common stock for $0.0001 a share with a seven-year term.

On August 9, 2023, in connection with the extension of the due date of the February 2022 loan, the May 2022 loan, the February 2023 letter agreement and the June 2023 letter agreement, the Company issued 2,000,000 common stock warrants at $0.20 per share with a five-year term. The fair value of this warrant was recorded as an expense of $177,086. This agreement also amended the terms of the previous warrant agreements from cash to cashless exercise. On December 29, 2023, in connection with the letter agreement discussed above, the life of this warrant was extended by two years.

18

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

7. WARRANTS (Continued)

The Company valued the impact of the two-year extension of the term on all of the above warrants using the Black-Scholes model based on the following significant inputs and recorded an expense of $29,000.

	5 Year	7 Year
Common stock price	$0.02	$0.02
Risk free interest rate	Between 3.8% and 4.0%	Between 3.8% and 3.9%
Stock volatility factor	Between 147% and 158%	Between 143% and 152%
Years to Maturity	Between 2.6 and 4.6 years	Between 4.6 and 6.6 years
Expected dividend yield	None	None

On March 31, 2024, the fair value of the derivative liability of the warrants was $66,065 and $728,991 as of September 30, 2023.

For the purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation of the derivatives are as follows:

Risk free interest rate	Between 4.2% and 4.3%
Stock volatility factor	Between 144% and 158%
Years to Maturity	Between 4.4 and 6.4 years
Expected dividend yield	None

8. OPTIONS

On June 2, 2020, the Company issued 2,000,000 options, on a post reverse split basis, to purchase common stock to the then directors of the Company as compensation for serving on the board during 2019. These options are exercisable on a cashless basis for a period of ten years from September 30, 2020, at an exercise price of $0.01 per share.

For the purpose of determining the fair market value of the options issued on June 2, 2020, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

Risk Free Interest Rate	0.32%
Stock Volatility Factor	146.0%
Weighted Average Expected Option Life	5 Years
Expected Dividend Yield	None

On March 13, 2023, the Company entered into non-qualified stock option agreements and granted vested ten-year options to purchase shares of the Company’s common stock for $0.175 a share, the closing price on the grant date. The Company issued options to purchase a total of 3,542,857 shares as follows: (a) 857,143 to each of the independent directors, (b) 428,571 to the chief financial officer, and 571,429 to the president of our StemVax Therapeutics subsidiary; (c) 57,143 to each of our scientific advisory board members; and (d) the remaining 542,857 to staff members and other service providers. The options are 100% vested and exercisable on the grant date and will expire on the tenth anniversary of the grant date on March 13, 2033. The stock-based compensation expense of $563,315 relating to the 2023 grants was recorded in the income statement on the grant date as the options are fully vested and exercisable on that date.

For the purpose of determining the fair market value of the options, the Company used the Black Scholes valuation model. The significant assumptions used in the Black Scholes valuation model for the options are as follows:

Risk Free Interest Rate	3.68%
Stock Volatility Factor	146.79%
Weighted Average Expected Option Life	5 Years
Expected Dividend Yield	None

19

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

8. OPTIONS (Continued)

A summary of the Company’s options activity and related information follows for the quarter ended March 31, 2024:

	March 31, 2024
			Weighted
	Number		average
	Of		exercise
	Options		price
Outstanding - beginning of period		5,542,857	$	0.115
Granted		-	$	-
Exercised		-	$	-
Forfeited		-	$	-
Outstanding - end of period		5,542,857	$	0.115

At March 31, 2024, the weighted average remaining contractual life of options outstanding:

		March 31, 2024
						Weighted
						Average
						Remaining
Exercisable		Options		Options		Contractual
Prices		Outstanding		Exercisable		Life (years)
$	.01		2,000,000		2,000,000		6.50
$	0.175		3,542,857		3,542,857		8.95

9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and accrued other current liabilities consisted of the following as of March 31, 2024, and September 30, 2023:

	March 31, 2024		September 30, 2023
Accrued liabilities		22,895		11,154
Interest payable		426,688		289,101
Provision for guaranteed commitment fees (1)		1,296,750		1,042,500
Accrued payroll		101,560		3,875
Deferred compensation		676,994		571,763
License Fees Payable		40,402		40,402
Insurance finance liability		77,053		23,772
	$	2,642,342	$	1,982,567

(1) Under the terms of the August 2021 Note, the February 2022 Note, the May 2022 Note, the February 2023 Letter Agreement and the June 19, 2023 Letter Agreement, the Company issued a total of 2,825,000 shares of common stock or pre-funded warrants as commitment fees. If the lender is unable to sell the shares for at least $1,325,000, it may make a one-time claim for each note to be reimbursed for the difference between their sale proceeds and $1,325,000. The difference between the fair value of the 2,825,000 shares as on March 31, 2024, and the guaranteed sale amount was recorded as a provision for guaranteed commitment fees and included in the table above.

20

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

10. DUE TO RELATED PARTIES

Due to Innovest Global

During the periods prior to the year ended September 30, 2022, Innovest Global, Inc. (“Innovest”) advanced funds to the Company for operating expenses in the amount of $86,217. As of March 31, 2024, the amount has not been reimbursed to Innovest. Our former Chairman Daniel Martin was the CEO of Innovest when the funds were advanced.

Due to TN3 LLC

On January 31, 2022, the Company entered into a preferred stock redemption agreement with Daniel G. Martin, at the time, sole board member and chairman, TN3, LLC, a company owned by Mr. Martin, Dwain K. Irvin, the chief executive officer, and Irvin Consulting, LLC, a company owned by Dr. Irvin. TN3 owned 25,000 shares of the Series B convertible preferred stock. Pursuant to the redemption agreement, on March 14, 2022, NovAccess redeemed 24,400 of the preferred shares and Irvin Consulting purchased 600 of the preferred shares from TN3. The Company also issued to TN3 1,502,670 shares of unregistered common stock, at $ 0.35 amounting to $525,934 which was equal to 10% of our outstanding common stock on the date the redemption agreement was signed. Upon completion of the redemption transaction, the Company was obligated to pay to TN3 a total of $250,000 over a period of eleven months, with payment accelerated if the Company raises at least $2.5 million of equity capital. As of March 31, 2024, the Company owed TN3 $95,000 of the redemption price and was in default.

Also in connection with closing the redemption transaction, on March 14, 2022, the Company entered into a common stock distribution agreement with Innovest Global, Inc. Innovest acquired 7.5 million shares of the common stock when Innovest sold StemVax, LLC to NovAccess in September 2020. Pursuant to the stock distribution agreement, Innovest agreed to distribute its NovAccess common stock to Innovest’s shareholders. Innovest has not completed the distribution.

11. COMMITMENTS AND CONTINGENCIES

There are no material pending legal proceedings to which we are a party, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers, or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

12. SUBSEQUENT EVENTS

Sumner Global Investment

On December 29, 2023, NovAccess Global Inc. entered into a securities purchase agreement (the “purchase agreement”) with Sumner Global LLC, an affiliate of Sumner Investment Group Inc. (“Sumner”), pursuant to which Sumner agreed to purchase 33.0 million newly issued shares of our unregistered common stock for $0.11 a share, or $3.63 million in total, and to loan us $7.05 million (collectively, the “transaction”). We expect to use this investment to fund operations and repay debt. Sumner is a global company that has created value across a diverse range of assets focusing on the procurement of products and services for governments and corporations around the world with an emphasis on healthcare, defense and logistics.

Sumner agreed to purchase the shares of common stock on or before January 31, 2023. Sumner agreed to make the loans in two tranches, with $3.05 million on February 15, 2024, and the remaining $4.0 million on March 15, 2024. The loans will be represented by convertible promissory notes that will have a five-year term, bear interest at 10% a year, and be convertible into shares of NovAccess common stock at $0.11 a share.

The transaction is subject to a number of contingencies, including Sumner completing its planned capital raise and there having been no material adverse effect on our business, operations, assets, financial condition or prospects. As a result, we cannot guarantee that the transaction will be completed when we expect, or whether the transaction will close at all.

Pursuant to the purchase agreement, Sumner has the right to appoint up to three new members to our board of directors. The purchase agreement also includes typical representations, warranties and covenants.

21

NOVACCESS GLOBAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024 AND 2023

12. SUBSEQUENT EVENTS (Continued)

As required by the purchase agreement, Irvin Consulting, LLC, a California limited liability company owned by our CEO Dwain K. Irvin, agreed to convert 600 shares of our Series B convertible preferred stock into 6.0 million shares of the Company’s unregistered common stock pursuant to the terms of the preferred stock (the “conversion”). The conversion will be effective upon our receipt of the $3.63 million purchase price for the common stock purchased by Sumner. Upon completion of the conversion, we will not have any shares of preferred stock outstanding.

The purchase agreement, including a form of convertible promissory note, is filed as an exhibit on Form 8-K. The description above is qualified in its entirety by reference to the full text of the purchase agreement.

As of the date of this report, the agreement has not been completed but based on assurances from Sumner is expected to close shortly.

Issuance of Common Shares

On various dates since March 31, 2024, the Holder of the April 24, 2023 Note has converted a further $18,510 of the principal balance into shares of common stock. The Company issued 3,085,000 shares of common stock for these conversions. The note was paid in full including interest on April 22, 2024 in the amount of $28,665.

On various dates since March 31, 2024, the Holder of the June 20, 2023 Note converted $21,380 of the principal balance into shares of common stock. The Company issued 5,405,711 shares of common stock for these conversions.

On various dates since March 31, 2024, the Holder of the August 16, 2023 Note converted $14,377 of the principal amount on the note for 3,100,000 shares of common stock.

Loan Agreements

On April 15, 2024, the Company received the final tranche of $25,000 payable under the February 27, 2024, Note.

On April 29, 2024, the Company received a further loan of $25,600. The terms include 2,500,000 common shares of the Company issued to the Holder of the Note.

On May 13, 2024, the Company paid $100,000 to the Holder of the June 20, 2023 Note and the August 17, 2023, Note as full settlement of all outstanding principal, interest and prepayment penalties on the two notes.

Also on May 13, 2024, the Company borrowed $117,000 from a third party. The terms include a 10% OID, interest of 12% per annum and 10,000,000 five-year prefunded warrants of which 3,000,000 may be repurchased by the Company for $1 if all amounts due to the Holder are paid within 90 days. The net proceeds from this loan were used to pay off the loans discussed above.

Extension of Due Dates on Loans

On April 23, 2024, the related parties of Jason Anderson and the Holder of the July 22, 2023, Note, at the request of the Company agreed to an extension of the loans due date to June 15, 2024.

On May 9, 2024, the Holder of the August 2022 Note agreed to an extension of the loan until August 10, 2024, in exchange for an interest rate change to 20% retroactive to August 9, 2022. The catch-up interest expense impact for the Company financials will be about $5,000.

On May 13, 2024, the Holder of the February 2002 Note, May 2022 Note, February 2023 Letter Agreement, June 19, 2023, Letter Agreement and December 29, 2023, Letter Agreement agreed to a further extension on their loans until May 31, 2024.

22

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary and Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed in this Quarterly Report and under “Item 1A: Risk Factors” in our Annual Report on Form 10-K for the year ended September 30, 2023.

We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this report. Readers should carefully review the factors described in other documents that the Company files from time to time with the SEC.

Organization

NovAccess Global Inc. is a Colorado corporation that was formerly known as XsunX, Inc. and Sun River Mining Inc.

Business Plan

In 2020, we transitioned our operations from solar contracting operations to the commercialization of developmental healthcare solutions in the biotechnology, medical, and health and wellness markets. On June 2, 2020, we entered into a membership interest purchase agreement with Innovest Global, Inc. to acquire StemVax, LLC (“StemVax”) for 7.5 million shares of our unregistered common stock. The acquisition was completed on September 8, 2020.

StemVax is a biopharmaceutical company developing novel therapies for brain tumor patients that holds an exclusive patent license from Cedars-Sinai Medical Center in Los Angeles, California (Cedars-Sinai) known as StemVax Glioblast (SVX-GB/TLR-AD1). TLR-AD1 specifically targets glioblastoma, the most common and lethal type of adult brain tumor. Christopher Wheeler, President of StemVax, has been involved in the pre-clinical research and development of the drug candidate at Cedars-Sinai Department of Neurosurgery since 1997. Dr. Wheeler began preparing the pre-IND application to obtain U.S. Food and Drug Administration (“FDA”) approval to start human clinical trials. In 2021, Dr. Wheeler led pre-IND interactions with the FDA and obtained a recommended roadmap from the FDA to facilitate the filing of an IND application for a Phase I application or a Phase IIa application. We currently plan to submit an IND application in 2024 if funding is available. In August 2022, we filed an application with the FDA for orphan drug designation (“ODD”) for TLR-AD1, which was granted in October 2022. Receiving ODD status represents a milestone in the development of TLR-AD1 and provides us with multiple incentives, including seven-year marketing exclusivity and federal tax credits, among other benefits.

We believe that investing in the biotechnology industry will significantly increase value for our shareholders. However, we cannot guarantee that we will be successful in this endeavor or that we can obtain the funding necessary to commercialize StemVax Glioblast or locate, acquire and finance the acquisition of additional biotechnology companies.

Recent Events

On April 22, 2024, we procured a new intellectual property license from Cedars-Sinai Medical Center to further advance the Company’s immunotherapy platform. The license pertains to the use of Isocitrate Dehydrogenase-1 (IDH1), a protein previously known to impact cell metabolism, to predict responsiveness to vaccine immunotherapy in treating highly malignant brain tumors such as glioblastoma multiforme (GBM). IDH1 is commonly mutated in brain and other tumors, but research published by the president of StemVax shows that it surprisingly predicts antitumor responses after vaccine therapy through a unique molecular mechanism. Because of this, IDH1 expression discerns long from short survivors after vaccine therapy in patients with brain tumors such as GBM.

23

Results of Operations for the three months ended March 31, 2024, compared to three months ended March 31, 2023

Revenue and Cost of Sales

The Company generated no revenue or cost of goods sold in the three months ended March 31, 2024, and 2023.

Selling, General and Administrative Expenses

Selling, general and administrative (SG&A) expenses decreased by $817,672 during the three months ended March 31, 2024, to $196,280 as compared to $1,013,952 for the three months ended March 31, 2023. The decrease in SG&A expenses during the three months ended March 31, 2024, was related primarily to stock-based compensation of $563,314 for options granted in the prior year quarter and warrants issued for value $148,500 in the prior year quarter with none in the current quarter. Also in the prior year the Company paid a commitment fee of 500,000 unregistered shares of the Company’s common stock for an expense of $82,500 for the February 2023 letter agreement and there was a continued reduction in consulting services for investor relations fees of $16,950 from the prior year.

Research and development expenses

The research and development expense marginally decreased by $4,761 for the three months ended March 31, 2024, to $36,275 as compared to $41,036 for the three months ended March 31, 2023. The primary reason for the decrease was on account of the decrease in costs for bio-technical services by $4,000.

Other Income/(Expenses)

Other expenses increased by $1,768,791 from other income of $1,508,752 for the three months ended March 31, 2023, to other expense of $260,039 for the three months ended March 31, 2024. The change was primarily due to the decrease in gain on change in derivative liability by $2,089,910. This was offset by the Company recording a lower expense for the make-whole provision on shares issued as loan commitment fees amounting to $165,375. The increase in other expenses was also partially offset by a reduction in interest expense of $155,744 during the current quarter because of lower debt amortization costs. The estimates of fair market value are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.

Net Income/(Loss)

For the three months ended March 31, 2024, our net loss was $492,594 as compared to a net income of $409,523 for the same period in 2023. The decrease in net income of $902,117 was due to the increase in other expenses on account of loss on change in derivative liability, partially offset by the decrease in SG&A, as described above.

Results of Operations for the six months ended March 31, 2024, compared to six months ended March 31, 2023

Revenue and Cost of Sales

The Company generated no revenue or cost of goods sold in the in the six months ended March 31, 2024, and 2023.

Selling, General and Administrative Expenses

Selling, general and administrative (SG&A) expenses decreased by $1,091,977 during the six months ended March 31, 2024, to $404,129 as compared to $1,496,106 for the six months ended March 31, 2023. The decrease in SG&A expenses during the six months ended March 31, 2024, was related primarily to stock-based compensation of $563,314 for options granted in the prior year and warrants issued for value $148,500 in the prior year period with none in the current period. Also in the prior year the Company paid a commitment fee of 500,000 unregistered shares of the Company’s common stock for an expense of $82,500 for the February 2023 letter agreement and there was a continued reduction in consulting services for investor relations fees of $240,691 from the prior year.

24

Research and development Expenses

The research and development expense increased by $9,972 for the six months ended March 31, 2024, to $85,972 as compared to $76,000 for the six months ended March 31, 2023. The increase was the result of more time spent on expanding our portfolio of intellectual property.

Other Income/(Expenses)

Other income increased by $1,906,636 from other expense of $605,536 for the six months ended March 31, 2023, to other income of $1,301,100 for the six months ended March 31, 2024. The change was primarily due to the Company recording an increase in gain on change in derivative liability of $1,850,627 and a reduction in interest expense of $384,384. These gains were offset by an increase in the make whole provision on shares issued as loan commitment fees amounting to $328,375 during the six months ended March 31, 2024. The estimates of fair market value are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.

Net Income/(Loss)

For the six months ended March 31, 2024, our net income was $810,999 as compared to a net loss of $2,221,883 for the same period in 2023. The increase in net income of $3,032,882 was due to the increase in other income related to the current period gain on derivatives and the decrease in SG&A as described above.

Liquidity and Capital Resources

We had a working capital deficit at March 31, 2024, of $6,853,896 as compared to a working capital deficit of $7,798,484, as of September 30, 2023. The decrease of $944,588 in the working capital deficit was the result of a decrease in the derivative liability amounting to $1,667,722, offset by accrual increases of $254,250 for guaranteed commitment fees, $202,916 related to deferred compensation and payroll and $137,587 for accrued interest.

For the six months ended March 31, 2024, our cash flow used by operating activities was $101,103 as compared to cash flow used by operating activities of $356,510 for the six months ended March 3l, 2023. The decrease in cash flow used by operating activities was due to reduced payments related to salaries, legal, accounting and other services which was also reflected in lower borrowings.

Cash flow used by investing activities was $0 during the six months ended March 31, 2024, and March 31, 2023.

Cash flow provided by financing activities was $89,500 for the six months ended March 31, 2024, as compared to cash provided by financing activities of $314,250 during the same period in 2023. The decrease in cash flow provided by financing activities reflects the difficulty in raising funds due to the delays in the proposed Sumner financing.

The Company will need to raise additional funds to finance its ongoing operations, complete its IND application to the FDA and to make payments under its loan agreements. We expect this will require at least $3.0 million through December 31, 2024. We plan to raise this capital through the issuance of additional common stock as well as obtaining additional debt as needed. On December 29, 2023, we entered into a securities purchase agreement with Sumner Global LLC, an affiliate of Sumner Investment Group Inc. (“Sumner”), pursuant to which Sumner agreed to purchase 33.0 million newly issued shares of our unregistered common stock for $0.11 a share, or $3.63 million in total, and to loan us $7.05 million. The transaction is subject to a number of contingencies, including Sumner completing its planned capital raise and there having been no material adverse effect on our business, operations, assets, financial condition or prospects. As a result, we cannot guarantee that the transaction will be completed when we expect, or whether the transaction will close at all.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships such as entities often referred to as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance-sheet arrangements or for other contractually narrow or limited purposes. As a result, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

25

Critical Accounting Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, the fair value of stock options, and derivative liabilities. Actual results could differ materially from those estimates.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Because NovAccess is a “smaller reporting company” as defined by the Securities and Exchange Commission, we are not required to provide additional market risk disclosure.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management team, with the participation of our chief executive officer, Dwain K. Irvin, and chief financial officer, Neil J. Laird, evaluated the effectiveness of the design and operation of NovAccess’ disclosure controls and procedures (as defined under the Securities Exchange Act) as of March 31, 2024. Based upon this evaluation, Messrs. Irvin and Laird concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2024.

Changes in Internal Control Over Financial Reporting

Our senior management team is responsible for establishing and maintaining adequate internal control over financial reporting, defined under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers, or persons performing similar functions, and effected by our board, senior management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. We continue to review our internal control over financial reporting and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

There was a change in our internal control over financial reporting identified in connection with the evaluation required by the Securities Exchange Act that occurred during our second fiscal quarter as we established enhanced review procedures to eliminate adjustments to our financial statements identified by our independent auditors.

26

Part II — Other Information

Item 1. Legal Proceedings.

We are not involved in any legal proceedings.

Item 1A. Risk Factors.

Please refer to the risk factors listed under “Item 1A: Risk Factors” in our Annual Report on Form 10-K for the year ended September 30, 2023, for information relating to certain risk factors applicable to NovAccess.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On April 11, 2023, we issued a convertible promissory note in the original principal amount of $79,250. For the six months ended March 31, 2024, the Holder converted the $79,250 principal plus $4,472 interest on the note into shares of common stock, leaving a principal balance of $0. We issued 6,953,792 shares of common stock for these conversions at an average price of $0.01204 per share. These issuances of shares were exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

On April 24, 2023, we issued a convertible promissory note in the original principal amount of $54,250. For the six months ended March 31, 2024, the Holder converted the $11,200 principal on the note into shares of common stock, leaving a principal balance of $43,050. We issued 1,396,509 shares of common stock for these conversions at an average price of $0.00802 per share. These issuances of shares were exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

For the three months ended March 31, 2024, we issued 208,752 unregistered shares of our common stock for accounting and investor relations services. 108,750 of these shares were issued to a related party.

The issuances of shares to our service providers were exempt from registration under Section 4(a)(2) of the Securities Act.

Item 3. Defaults Upon Senior Securities.

During the quarter ended March 31, 2024, NovAccess was not in material default with respect to any of its material indebtedness.

Item 4. Mine Safety Disclosures.

We are not engaged in mining operations.

Item 5. Other Information.

We have disclosed on Form 8-K all reportable events that occurred in the quarter ended March 31, 2024.

Item 6. Exhibit and Financial Statement Schedules.

(a) Financial Statement Schedules (see Item 1 Financial Statements and Supplementary Data)

(b) Exhibits

Exhibit	Description
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Dwain K. Irvin
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Neil J. Laird
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
101	The following materials from the NovAccess Global Inc. Quarterly Report on Form 10-Q for the period ended March 31, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language):
	(i) the Condensed Consolidated Balance Sheets as of March 31, 2024 and September 30, 2023
	(ii) the Condensed Consolidated Statements of Operations for the Three and Six Months Ended March 31, 2024 and March 31, 2023,
	(iii) the Condensed Consolidated Statements of Shareholders’ Deficit for the Three and Six Months Ended March 31, 2024 and March 31, 2023,
	(iv) the Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended March 31, 2024 and March 31, 2023, and
	(v) Related Notes to the Condensed Consolidated Financial Statements
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

27

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, NovAccess has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NovAccess Global Inc.
Date: May 15, 2024	/s/ Dwain K. Irvin
	By Dwain K. Irvin, Chief Executive Officer
	(Principal Executive Officer)
Date: May 15, 2024	/s/ Neil J. Laird
	Neil J. Laird, Chief Financial Officer
	(Principal Financial and Accounting Officer)

28